--- title: "Senti Biosciences adjourns annual meeting to seek more votes for merger proposal" url: "https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-10-13" section: "Mergers" tickers: "NASDAQ:SNTI" source: "https://www.sec.gov/Archives/edgar/data/1854270/000162828026065685/snti-20261008.htm" summary: "Senti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 mill" --- By the aibio.space news desk. Sources - [Senti Biosciences Holdings, Inc. 8-K (2026-10-13)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065685/snti-20261008.htm) - [Senti Biosciences Holdings, Inc. 10-K (2026-03-27): business](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/snti-20251231.htm) - [Senti Biosciences Holdings, Inc. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021580/) [SNTI](https://aibio.space/companies/senti-biosciences/) 2026-10-13 # Senti Biosciences adjourns annual meeting to seek more votes for merger proposal Tickers [SNTI](https://aibio.space/companies/senti-biosciences/) Senti adjourned its October 8, 2026 annual meeting without conducting any business to seek more votes for a merger proposal. The company reported $6.5 million of cash and cash equivalents at June 30, 2026, after using $43.4 million in operations in 2025. ## Key facts - **Company**: Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) - **News type**: Mergers - **Primary source**: [Senti Biosciences Holdings, Inc. 8-K (2026-10-13)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026065685/snti-20261008.htm) *An empty boardroom with a long table. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The adjournment Senti Biosciences Holdings, Inc. (Nasdaq: [SNTI](https://aibio.space/companies/senti-biosciences/)) convened its virtual 2026 Annual Meeting of Stockholders on October 8, 2026, and adjourned it without conducting any business. In a Form 8-K filed October 13, 2026, the company said a quorum was present, but it adjourned the meeting to have more time to solicit votes from stockholders in favor of the Merger Agreement Proposal. The proposal is defined in the definitive proxy statement the company filed on September 24, 2026. The 8-K does not describe the merger terms. It says no changes have been made to the proposals and that all polls will remain open. It does not say how many votes the company had received for the merger proposal when it adjourned, so the size of any shortfall is not disclosed. The meeting reconvenes on Thursday, October 15, 2026, at 8:00 a.m. Pacific time, online. The record date remains September 23, 2026. Stockholders who already voted and do not want to change their vote need not take any action. The company urged holders to read the proxy statement before voting. ## The lead program and its data Senti calls itself a "clinical-stage biotechnology company developing next-generation cell and gene therapies" built on a gene circuit platform. Its most advanced program is SENTI-202, an off-the-shelf CAR-NK cell therapy for relapsed or refractory hematologic malignancies, including acute myeloid leukemia (AML). It is being studied in an open-label Phase 1 trial in the United States and Australia. The company reported results for twenty AML patients treated in that trial in 2024 and 2025. Of those patients, 50% had an overall response, and 42% achieved a CR/CRh. The company said 100% of the complete responses and 83% of all responses were assessed as measurable residual disease negative at the recommended phase 2 dose. It reported a median duration of composite complete remission of 7.6 months across all patients. The company itself calls these the initial clinical data. They come from twenty patients in an open-label study, which is too small to show how often the therapy works in a wider population of patients with the disease. The company says all patients treated with SENTI-202 showed a favorable safety profile, but it offers that as a general statement without numbers. The FDA granted orphan drug designation to SENTI-202 for relapsed or refractory hematologic malignancies, including AML, which the company announced on June 18, 2025. On December 9, 2025, the company announced that the FDA had also granted regenerative medicine advanced therapy (RMAT) designation, based on data from the ongoing Phase 1 trial. Senti's annual report also lists preclinical programs. One is a solid tumor cell therapy program. Another is a partnership with BlueRock Therapeutics, Inc. to develop cell therapies for regenerative medicine. The company's stated strategy includes partnering to support indications beyond oncology. ## Cash and the money Senti's financial data from its annual report show a net loss of $61.4 million for 2025, against $52.8 million for 2024. Research and development expense was $37.6 million in 2025 and $34.4 million in 2024. The company used $43.4 million in operations in 2025, compared with $41.4 million in 2024. Cash and cash equivalents were $48.3 million at the end of 2024 and $16.4 million at the end of 2025. The company's quarterly report puts cash and cash equivalents at $6.5 million as of June 30, 2026. The 8-K does not address the company's cash position, any plan to raise money, or how the merger would be financed. The next dated step is the reconvened vote on October 15, 2026. The 8-K does not describe what the company would do after that vote. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story SNTI Senti Biosciences Holdings, Inc. NASDAQ ยท United States Open the starter desk ## More in Mergers Mergers ### [InMed sets November 5 record date for CVRs tied to Mentari merger](https://aibio.space/news/inmed-sets-november-5-record-date-cvrs-tied-mentari-merger/) Oct 27, 2026 Mergers ### [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/) Oct 26, 2026 Mergers ### [Skye Bioscience files preliminary proxy for its Redx Pharma acquisition](https://aibio.space/news/skye-bioscience-files-preliminary-proxy-redx-pharma-acquisition/) Oct 26, 2026 --- Source page: https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Senti Biosciences adjourns annual meeting to seek more votes for merger proposal", 2026-10-13, https://aibio.space/news/senti-biosciences-adjourns-annual-meeting-seek-more-votes-merger/